{"nctId":"NCT02369835","briefTitle":"Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy","startDateStruct":{"date":"2015-05"},"conditions":["Head and Neck Carcinoma","Radiation-Induced Dermatitis"],"count":132,"armGroups":[{"label":"Arm I (modified Dakin's solution)","type":"EXPERIMENTAL","interventionNames":["Drug: Dakin's solution"]},{"label":"Arm II (placebo)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Dakin's solution","otherNames":["Sodium hypochlorite in aqueous solution","Dakin's fluid","Liquid bleach"]},{"name":"Placebo","otherNames":["PLCB"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Head and neck cancer who plan to undergo radiation therapy to the head and neck region\n* At least 18 years of age\n* Able to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior radiation therapy to the head and neck region or prior chemotherapy for head and neck cancer (induction chemotherapy NOT excluded)\n* The physician-approved radiation treatment plan indicates a maximum prescription dose of less than 45 Gy\n* Scleroderma or discoid lupus","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Radiation Dermatitis","description":"Participants were assessed for radiation dermatitis on the arms according to the Stanford Radiation Dermatitis Scoring System (SRDSS), at baseline and through their treatment course. The outcome is reported by treatment group as the number and proportion of participants that experience SRDSS Grade E or greater radiation dermatitis through 10 weeks after completion of radiation treatment, a number without dispersion.\n\nSRDSS, by grade:\n\n* A. No skin change\n* B. Faint, barely detectable erythema\n* C. Follicular rash, hyperpigmentation, evolving erythema\n* D. Dry desquamation, brisk erythema\n* E. Moist desquamation\n* F. Bleeding, ulceration, and/or infection\n\nSRDSS Grade E is roughly equivalent to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 Grade 3 radiation dermatitis, \"Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion\"","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Grade E Radiation Dermatitis","description":"Participants were assessed for radiation dermatitis on the arms according to the Stanford Radiation Dermatitis Scoring System (SRDSS), at baseline and through their treatment course. The time that SRDSS Grade E radiation dermatitis developed was noted. The outcome is reported by treatment group as the mean time to development of SRDSS Grade E radiation dermatitis, with standard deviation.\n\nSRDSS, by grade:\n\n* A. No skin change\n* B. Faint, barely detectable erythema\n* C. Follicular rash, hyperpigmentation, evolving erythema\n* D. Dry desquamation, brisk erythema\n* E. Moist desquamation\n* F. Bleeding, ulceration, and/or infection\n\nSRDSS Grade E is roughly equivalent to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 Grade 3 radiation dermatitis, \"Moist desquamation in areas other than skin folds and creases; bleeding induced by minor trauma or abrasion.\"\n\nAdditional information describing this outcome is not available.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Pain Associated With Radiation Dermatitis","description":"Quality of life was assessed as pain associated with radiation dermatitis. Assessments were baseline and through treatment follow-up 3 to 12 weeks after completion of radiation treatment. The assessment was to be conducted with a Modified Brief Pain Inventory (MBPI), a 13-question survey with responses ranging from 0 to 10, and an overall score of 0 to 130. A higher score indicates more pain and less quality of life. The outcome was to be reported by treatment group as the mean score with standard deviation.\n\nAdditional information describing this outcome is not available.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":64},"commonTop":["Radiation dermatitis","Abdominal pain","Bloating","Mucositis","Nausea"]}}}